company background image
OCUL

Ocular TherapeutixNasdaqGM:OCUL Stock Report

Market Cap

US$857.0m

7D

14.8%

1Y

8.6%

Updated

17 Oct, 2021

Data

Company Financials +
OCUL fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

OCUL Overview

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology.

Ocular Therapeutix Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ocular Therapeutix
Historical stock prices
Current Share PriceUS$11.19
52 Week HighUS$9.11
52 Week LowUS$24.30
Beta2.1
1 Month Change6.07%
3 Month Change-8.28%
1 Year Change8.64%
3 Year Change81.36%
5 Year Change62.65%
Change since IPO-14.91%

Recent News & Updates

Sep 16
Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Aug 09

Ocular Therapeutix: Why I'm Buying The Dip

OCUL has dropped substantially since a December 2020 stock offering. It is a platform company with already approved products. In my view, the approved products justify the current beaten down valuation, leaving plenty of blue sky for the remaining pipeline.

Jun 12
Most Shareholders Will Probably Find That The CEO Compensation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Is Reasonable

Most Shareholders Will Probably Find That The CEO Compensation For Ocular Therapeutix, Inc. (NASDAQ:OCUL) Is Reasonable

Performance at Ocular Therapeutix, Inc. ( NASDAQ:OCUL ) has been reasonably good and CEO Antony Mattessich has done a...

Shareholder Returns

OCULUS PharmaceuticalsUS Market
7D14.8%-0.04%2.0%
1Y8.6%11.5%27.6%

Return vs Industry: OCUL underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.

Return vs Market: OCUL underperformed the US Market which returned 27.6% over the past year.

Price Volatility

Is OCUL's price volatile compared to industry and market?
OCUL volatility
OCUL Beta2.1
Industry Beta0.65
Market Beta1

Stable Share Price: OCUL is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: OCUL's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006181Antony Mattessichhttps://www.ocutx.com

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant administered by the fine-gauge needle that is in phase 1 clinical trial for the treatment of wet age-related macular degeneration; OTX-TIC, a travoprost intracameral implant, which is in phase 1 clinical trial for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that is in phase 2 clinical trial for the chronic treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trial for the short-term treatment of the signs and symptoms of dry eye disease.

Ocular Therapeutix Fundamentals Summary

How do Ocular Therapeutix's earnings and revenue compare to its market cap?
OCUL fundamental statistics
Market CapUS$856.96m
Earnings (TTM)-US$102.92m
Revenue (TTM)US$32.29m

26.5x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OCUL income statement (TTM)
RevenueUS$32.29m
Cost of RevenueUS$42.48m
Gross Profit-US$10.19m
ExpensesUS$92.72m
Earnings-US$102.92m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.34
Gross Margin-31.57%
Net Profit Margin-318.76%
Debt/Equity Ratio62.6%

How did OCUL perform over the long term?

See historical performance and comparison

Valuation

Is Ocular Therapeutix undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: OCUL ($11.19) is trading below our estimate of fair value ($113.74)

Significantly Below Fair Value: OCUL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: OCUL is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: OCUL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OCUL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OCUL is overvalued based on its PB Ratio (10.7x) compared to the US Pharmaceuticals industry average (3.1x).


Future Growth

How is Ocular Therapeutix forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

56.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: OCUL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: OCUL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: OCUL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: OCUL's revenue (42.2% per year) is forecast to grow faster than the US market (9.9% per year).

High Growth Revenue: OCUL's revenue (42.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if OCUL's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Ocular Therapeutix performed over the past 5 years?

-22.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OCUL is currently unprofitable.

Growing Profit Margin: OCUL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OCUL is unprofitable, and losses have increased over the past 5 years at a rate of 22% per year.

Accelerating Growth: Unable to compare OCUL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCUL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: OCUL has a negative Return on Equity (-128.25%), as it is currently unprofitable.


Financial Health

How is Ocular Therapeutix's financial position?


Financial Position Analysis

Short Term Liabilities: OCUL's short term assets ($216.5M) exceed its short term liabilities ($21.6M).

Long Term Liabilities: OCUL's short term assets ($216.5M) exceed its long term liabilities ($128.9M).


Debt to Equity History and Analysis

Debt Level: OCUL's debt to equity ratio (62.6%) is considered high.

Reducing Debt: OCUL's debt to equity ratio has increased from 22% to 62.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCUL has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if OCUL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is Ocular Therapeutix current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OCUL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OCUL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OCUL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OCUL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OCUL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.3yrs

Average management tenure


CEO

Antony Mattessich (54 yo)

4.25yrs

Tenure

US$2,163,150

Compensation

Mr. Antony Mattessich serves as Director of Aura Biosciences, Inc. since September 2021. He has been the Chief Executive Officer and President of Ocular Therapeutix, Inc. since July 26, 2017. Mr. Mattessic...


CEO Compensation Analysis

Compensation vs Market: Antony's total compensation ($USD2.16M) is about average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Antony's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OCUL's management team is considered experienced (3.3 years average tenure).


Board Members

Experienced Board: OCUL's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OCUL insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9%.


Top Shareholders

Company Information

Ocular Therapeutix, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Ocular Therapeutix, Inc.
  • Ticker: OCUL
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$856.963m
  • Shares outstanding: 76.58m
  • Website: https://www.ocutx.com

Number of Employees


Location

  • Ocular Therapeutix, Inc.
  • 24 Crosby Drive
  • Bedford
  • Massachusetts
  • 1730
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/17 22:19
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.